San Juan Capistrano, CA – According to filings with the U.S. Securities and Exchange Commission, Allegro Ophthalmics is raising $6,738,545.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Scott Cooper played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Allegro Ophthalmics

Allegro Ophthalmics, LLC is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class of drugs for the treatment of retinal diseases. Allegro’s lead investigational drug, risuteganib (Luminate), a broad-spectrum integrin inhibitor, downregulates oxidative stress upstream, at its source, simultaneously affecting all four pathways of oxidative stress that contribute to retinal diseases such as diabetic macular edema (DME) and nonexudative age-related macular degeneration (dry AMD).

To learn more about Allegro Ophthalmics, visit http://www.allegroeye.com/

Contact:
Scott Cooper, Chief Financial Officer
949-940-8130
scooper@allegroeye.com
https://www.linkedin.com/in/scott-cooper-12a22075/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved